SWOG clinical trial number
SWOG-9235

Phase II Trial of Casodex in Advanced Prostate Cancer Patients Who Failed Conventional Hormonal Manipulation

Closed
Phase
Accrual
96%
Published
Abbreviated Title
Phase II Trial of Casodex in Advanced Prostate Cancer Patients Who Failed Conventional Hormonal Manipulation
Activated
12/15/1993
Closed
06/01/1994

Research committees

Genitourinary Cancer

Publication Information Expand/Collapse

2001

Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235)

O Kucuk;E Fisher;CM Moinpour;D Coleman;MHA Hussain;AO Sartor;GS Chatta;BA Lowe;MA Eisenberger;ED Crawford Urology 58(1):53-58

2000

Behavioral science research in the cooperative group setting: the Southwest Oncology Group Experience

CC Gotay;CM Moinpour;S Moody-Thomas;ER Gritz;KS Albain;E DeAntoni;L Hansen;PA Ganz Journal of the National Cancer Institute 92(17):1381-1387

1996

Phase II trial of casodex in advanced prostate cancer (CaP) patients who failed conventional hormonal manipulation: A Southwest Oncology Group (SWOG) study (SWOG9235).

O Kucuk;B Blumenstein;C Moinpour;D Lew;D Coleman;M Eisenberger;D Crawford American Society of Clinical Oncology 15:245(#618)

Other Clinical Trials

SWOG Clinical Trial Number
S2427

Single Arm Phase II Study of Bladder Preservation with Immunoradiotherapy after a Clinically Meaningful Response to Neoadjuvant Therapy in Patients with Muscle Invasive Bladder Cancer (BRIGHT)
Research Committee(s)
Genitourinary Cancer
Activated
09/04/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CCTG-PR26

A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (TRIPLE-SWITCH)
Research Committee(s)
Genitourinary Cancer
Activated
01/30/2025
Open
Phase
SWOG Clinical Trial Number
S2312

A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
7%
Open
Phase